Cargando…

B7 family protein glycosylation: Promising novel targets in tumor treatment

Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Linlin, Guan, Xiaoyan, Xiang, Mingli, Wang, Qian, Long, Qian, Yue, Chaoyi, Chen, Lulu, Liu, Jianguo, Liao, Chengcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763287/
https://www.ncbi.nlm.nih.gov/pubmed/36561746
http://dx.doi.org/10.3389/fimmu.2022.1088560
_version_ 1784853023372083200
author Xiao, Linlin
Guan, Xiaoyan
Xiang, Mingli
Wang, Qian
Long, Qian
Yue, Chaoyi
Chen, Lulu
Liu, Jianguo
Liao, Chengcheng
author_facet Xiao, Linlin
Guan, Xiaoyan
Xiang, Mingli
Wang, Qian
Long, Qian
Yue, Chaoyi
Chen, Lulu
Liu, Jianguo
Liao, Chengcheng
author_sort Xiao, Linlin
collection PubMed
description Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immunomodulatory ligand B7 family with corresponding receptors induces or inhibits T cell responses by sending co-stimulatory and co-inhibitory signals respectively. Blocking the glycosylation of the B7 family members PD-L1, PD-L2, B7-H3, and B7-H4 inhibited the self-stability and receptor binding of these immune checkpoint proteins, leading to immunosuppression and rapid tumor progression. Therefore, regulation of glycosylation may be the “golden key” to relieve tumor immunosuppression. The exploration of a more precise glycosylation regulation mechanism and glycan structure of B7 family proteins is conducive to the discovery and clinical application of antibodies and small molecule inhibitors.
format Online
Article
Text
id pubmed-9763287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97632872022-12-21 B7 family protein glycosylation: Promising novel targets in tumor treatment Xiao, Linlin Guan, Xiaoyan Xiang, Mingli Wang, Qian Long, Qian Yue, Chaoyi Chen, Lulu Liu, Jianguo Liao, Chengcheng Front Immunol Immunology Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immunomodulatory ligand B7 family with corresponding receptors induces or inhibits T cell responses by sending co-stimulatory and co-inhibitory signals respectively. Blocking the glycosylation of the B7 family members PD-L1, PD-L2, B7-H3, and B7-H4 inhibited the self-stability and receptor binding of these immune checkpoint proteins, leading to immunosuppression and rapid tumor progression. Therefore, regulation of glycosylation may be the “golden key” to relieve tumor immunosuppression. The exploration of a more precise glycosylation regulation mechanism and glycan structure of B7 family proteins is conducive to the discovery and clinical application of antibodies and small molecule inhibitors. Frontiers Media S.A. 2022-12-06 /pmc/articles/PMC9763287/ /pubmed/36561746 http://dx.doi.org/10.3389/fimmu.2022.1088560 Text en Copyright © 2022 Xiao, Guan, Xiang, Wang, Long, Yue, Chen, Liu and Liao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xiao, Linlin
Guan, Xiaoyan
Xiang, Mingli
Wang, Qian
Long, Qian
Yue, Chaoyi
Chen, Lulu
Liu, Jianguo
Liao, Chengcheng
B7 family protein glycosylation: Promising novel targets in tumor treatment
title B7 family protein glycosylation: Promising novel targets in tumor treatment
title_full B7 family protein glycosylation: Promising novel targets in tumor treatment
title_fullStr B7 family protein glycosylation: Promising novel targets in tumor treatment
title_full_unstemmed B7 family protein glycosylation: Promising novel targets in tumor treatment
title_short B7 family protein glycosylation: Promising novel targets in tumor treatment
title_sort b7 family protein glycosylation: promising novel targets in tumor treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763287/
https://www.ncbi.nlm.nih.gov/pubmed/36561746
http://dx.doi.org/10.3389/fimmu.2022.1088560
work_keys_str_mv AT xiaolinlin b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT guanxiaoyan b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT xiangmingli b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT wangqian b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT longqian b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT yuechaoyi b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT chenlulu b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT liujianguo b7familyproteinglycosylationpromisingnoveltargetsintumortreatment
AT liaochengcheng b7familyproteinglycosylationpromisingnoveltargetsintumortreatment